Gross to Net Planning

Gross to Net Planning

Two Labs’ Gross to Net Solutions team partners with pharma manufacturers to determine accurate expenses and revenue so they can create operations and funding plans that meet their needs. Our analyses are grounded in experience – we have led over 200 relevant projects – which can significantly improve a launch plan if done at the beginning of the process.

Our Gross to Net Principles

Think Beyond the Model

A gross to net model is only as good as the assumptions and philosophy that drive it. Manufacturers need to be able to answer questions like:

How does gross to net differ by channel?

How can we influence gross to net?

Should we invest our dollars with payers? With patients?

What assumptions should we use?

With specialty products, what are the expenses we need to expect for launching?

What is the Market Access strategy?

Everything Must Be Accounted For

The first step with developing an accurate gross to net model is making sure all expenses are accounted for. This can change based on the type of drug you are launching, but generally it’s:

Fair market value and appropriate assumptions

The current pharma climate

Channel / 3PL costs

Copay assistance

Patient assistant program costs

Specialty pharmacy costs

Market Access / Payer fees

Government pricing

Emerging Pharma Should not Rely on Large Pharma Models

In many cases, we have seen CFOs at emerging manufacturers rely on previous experience at a big pharma company. But costs are different when working at a smaller scale, and how gross to net was predicted in large pharma isn’t likely to translate very well into the emerging pharma market.

Gross to Net Planning Is an Ongoing Project

Creating your gross to net model isn’t a singular part of the process, but rather it needs to continually be evaluated and adjusted according to any decisions that are made as part of the launch. The result of a comprehensive gross to net process such as this is an accurate and efficient picture of finances which informs a unique and effective funding, operations, and sales plan.

Our Gross to Net Principles

At Two Labs, we’ve seen unprepared launches miss their gross to net target by more than 15%, which completely disrupts a business case for a new drug. Our experience with more than 200 relevant projects helps you plan for and respond to every evolving detail necessary to avoid making costly mistakes. Understanding the key elements early pre-launch is crucial to ensuring all expenses are being accounted for in the forecasting models.

Get in touch with our Commercial Finance team for a free consultation to talk about how to create a successful gross to net plan for your new pharma product.

Get on the Smartest Route to Your Pharma Product Journey with Two Labs

We Lead Pharma Manufacturers Through the Commercial Strategy and Operations Journey

We Have Deep Experience Supporting Pharma Manufacturers

NEW PRODUCT LAUNCHES
130 +
IN-MARKET PROJECTS
210 +
YEARS OF EXPERIENCE
0 +

Let's Talk

Leverage our strategic expertise to bring greater certainty to your gross to net forecasting.

Additional Commercial Finance Insights

Not all Gross to Net is Created Equal

The COVID-19 pandemic is unprecedented and unpredictable. Nevertheless, we are remaining flexible as we continue to support pharmaceutical manufacturers and their life-changing work.

We’re here to support your success from clinical to commercial – and beyond.

How can we help you today?